Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
Boehringer-Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $95,000,000 |
Janssen Pharmaceuticals | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | WV-AG | $99,000,000 |
Cephalon Inc. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $116,000,000 |
Warner Chilcott PLC | AbbVie | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
Allergan Ltd. et al. | AbbVie | off-label or unapproved promotion of medical products | 2022 | FL-AG | $134,200,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2024 | WA-AG | $149,500,000 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $150,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | TX-AG | $158,000,000 |
Forest Pharmaceuticals Inc. | AbbVie | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
Endo Health Solution | Endo International | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
Endo Health Solutions Inc. | Endo International | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
Allergan Finance LLC | AbbVie | off-label or unapproved promotion of medical products | 2021 | NY-AG | $200,000,000 |
Merck Sharp & Dohme Corp. | Merck | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $201,975,000 |
Elan Corporation PLC | Perrigo | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | TX-AG | $225,000,000 |
Wyeth Pharmaceuticals, Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
Serono Inc. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $262,000,000 |
Purdue Pharma | Purdue Pharma | Controlled Substances Act violation | 2019 | OK-AG | $270,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | FL-AG | $278,826,499 |
Indivior plc | Indivior PLC | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $300,000,000 |
Teva Pharmaceuticals, Ltd. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | NY-AG | $313,343,793 |
Abbott Laboratories | AbbVie | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $339,148,643 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
Cephalon Inc | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2008 | FDA | $425,000,000 |
Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | FDA | $430,000,000 |
Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | USAO | $435,000,000 |
Endo International plc | Endo International | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $450,000,000 |
GlaxoSmithKline | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
Wyeth Pharmaceuticals Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $515,000,000 |
AstraZeneca LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
Allergan Inc. | AbbVie | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $612,000,000 |
Serono, S.A. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | FDA | $704,000,000 |
Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
Merck, Sharp & Dohme | Merck | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
Abbott Laboratories Inc. | AbbVie | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
Mallinckrodt | Mallinckrodt | Controlled Substances Act violation | 2020 | MULTI-AG | $1,600,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $2,370,000,000 |
GlaxoSmithKline LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $4,250,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $5,000,000,000 |